Xi'an Jiaotong University

Jian-Gang Long

Jian-Kang Liu

Xu-Yun Liu

Zhen Wang

Qing-Qing Ma

Jing Lou

Lin Zhao

Yu-Xia Zhang

Yong-Yao Wang

Qing-Lin Jiang

Xiao-Hong Xu

Ya-Chong Hu

Cai-Yue Zhu

Ting-Hua Zhang

The disclosure relates to a pharmaceutical composition including daphnetin, a method for improving aortic endothelial cell function, and use of daphnetin in preparation of a medicine for improving aortic endothelial cell function. The daphnetin is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The daphnetin is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid.

Use of daphnetin in improving function of aortic endothelial cell

The disclosure relates to a compound, 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, for improving aortic endothelial cell function and use thereof. The compound is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The compound is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid, for example, increasing the expression of mitochondrial complex I.

2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, composition, and method for improving function of aortic endothelial cell

Growing community of inventors

Xi'an, China

Jian-Gang Long